VivoSeq
Other

Jaundice

9

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Jaundice is an early-stage landscape with 9 programs across 5 companies. The most active players are InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company, Novartis, POLYSAN Scientific & Technological Pharmaceutical Company. 1 therapy is approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2P

POLYSAN Scientific & Technological Pharmaceutical Company

2 programs

Phase 3A

Arbor Pharmaceuticals, Inc.

1 program

ApprovedC

Calm Water Therapeutics LLC

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

10

clinical trials

Completed9 · 90%
Unknown status1 · 10%

Clinical Trials

Trial Activity

10 trials

Remaxol® in Mechanical Jaundice of Non-malignant Origin
Completed·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 3·NCT03418935·342 enrolled
Application of n-3 Fatty to Patient of Jaundice
Completed·HHuazhong University of Science and Technology·N/A·NCT03376945·106 enrolled
Stannsoporfin With Light Therapy for Newborn Babies With Jaundice
Completed·IInfaCare Pharmaceuticals Corporation, a Mallinckrodt Company·Phase 2·NCT01887327·91 enrolled
Remaxol® in Malignant Mechanical Jaundice
Completed·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 3·NCT03416062·240 enrolled
Glycerin Suppositories to Reduce Jaundice in Premature Infants
Completed·UUniversity of Rochester·N/A·NCT01746511·79 enrolled
Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of N-acetylcysteine Supplementation in Patients With Hepatic and Post Hepatic Jaundice
Completed·TTanta University·Phase 2·NCT06236165·44 enrolled
Ceftriaxone and Jaundice in Neonates
Completed·UUniversity of Rochester·N/A·NCT03133637·27 enrolled
The Effects of Dexamethasone Administration on Jaundice Following Liver Resection
Completed·SShanghai Zhongshan Hospital·Phase 2/3·NCT02991339·76 enrolled
Effect of Oral Zinc Sulfate on Jaundice in Neonates Admitted to Neonatal Intensive Care Unit
Completed·MMakassed General Hospital·N/A·NCT05161611·60 enrolled
Cholinergic Anti-inflammatory Pathway in Prevention & Treatment of the SIRS in Patients With Jaundice After Operation.
Unknown status·—·Phase 1/2·NCT02279147·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)